| 前收盘价格 | 294.98 |
| 成交量 | 1,272,503 |
| 预期市盈率 (P/E Forward) | 18.12 |
| 价格/销量 (P/S) | 7.89 |
| 52周波幅 | |
| 股息率 (DY TTM) | 3.18% |
| 营业毛利率 | 7.31% |
| 营业利益率 (TTM) | 30.43% |
| 稀释每股收益 (EPS TTM) | 2.35 |
| 季度收入增长率 (YOY) | 8.40% |
| 季度盈利增长率 (YOY) | -6.10% |
| 总债务/股东权益 (D/E MRQ) | 4,789.60% |
| 流动比率 (MRQ) | 0.760 |
| 营业现金流 (OCF TTM) | 16.40 B |
| 杠杆自由现金流 (LFCF TTM) | 16.94 B |
| 资产报酬率 (ROA TTM) | 8.34% |
| 股东权益报酬率 (ROE TTM) | 88.40% |
新闻情绪
正面
AIStockmoo 评分
| 价值 35% | -4.2 |
| AI Insight 参考 | -4.2 |
| 相对估值 参考 | NA |
| 财务健康 参考 | -0.7 |
| 时机 35% | 2.0 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 4.0 |
| 技术平均移动指标 参考 | -1.0 |
| 聪明钱 30% | 0.8 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 新闻情绪 参考 | 2.9 |
| 市场环境 | ×1.08 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | +10.4% |
| 支柱一致性 | ×0.86 |
| 不计入评分 | |
| 价格波动 参考 | -3.0 |
| 最终评分 | -0.48 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - General (US) | 混合的 | 看涨 |
| Drug Manufacturers - General (全球的) | 混合的 | 看涨 | |
| 股票 | AbbVie Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| ABBV | - | 3.18% | - | - |
| JNJ | - | 1.92% | - | 8.29 |
| PFE | - | 6.00% | - | 1.85 |
| NVO | - | 4.16% | - | 5.49 |
| GSK | - | 3.66% | - | 4.14 |
| BMY | - | 4.36% | - | 5.48 |
|
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - General |
| 投资方式 | Large Value |
| 内部持股比例 | 0.10% |
| 机构持股比例 | 74.87% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
AbbVie (ABBV) Reports Positive Phase 3 QULIPTA Migraine Trial Results
AbbVie (NYSE:ABBV) reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention against topiramate. The TEMPLE study found QULIPTA achieved superior tolerability compared with topiramate in adults with migraine. QULIPTA also showed better efficacy than topiramate on key… |
| 12 Nov 2026 | Yahoo Finance |
Coca-Cola or AbbVie: The One Dividend Stock I’d Hold for the Next 20 Years
Key TakeawaysAbbVie raised its quarterly dividend 5. 2% to $1… |
| 12 Nov 2026 | Yahoo Finance |
The Zacks Analyst Blog Highlights NVIDIA, Walmart, AbbVie, Pioneer Bancorp and Aspira
NVDA, WMT and ABBV headline Zacks' latest research, with growth drivers and business risks shaping their investment outlooks. |
| 12 Nov 2026 | Yahoo Finance |
AbbVie Deal Altering The Investment Case For Nxera Pharma Stock (TSE:4565)?
Nxera Pharma announced in early November 2026 that its UK subsidiary entered an exclusive global license agreement with AbbVie for the EP4 agonist program in inflammatory bowel disease. The agreement includes a US$100 million upfront payment and potential milestones up to US$1.37 billion, plus… |
| 11 Nov 2026 | Yahoo Finance |
Top Analyst Reports for NVIDIA, Walmart & AbbVie
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Walmart Inc. (WMT), AbbVie Inc. (ABBV) as well as two micro-cap stocks, Pioneer Bancorp, Inc. (PBFS) and Aspira Women's Health Inc. (AWHL). |
| 11 Nov 2026 | Yahoo Finance |
ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?
AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges. |
| 11 Nov 2026 | Yahoo Finance |
3 Legacy Health Care Dividend Stocks That Never Go Out of Style
Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsuits, one plans a spinoff, and one raises its payout by a single cent. |
| 10 Nov 2026 | Yahoo Finance |
Can AbbVie (ABBV) Justify Its Valuation After Raised Guidance And Strong Results?
AbbVie (ABBV) just raised its full year 2026 revenue guidance to about US$67.8b and lifted its dividend, after reporting third quarter sales of US$17.4b and net income of US$4.2b. Recent price action has been strong, with AbbVie’s share price delivering a 6.1% 1 month gain and a 17.3% 3 month share… |
| 股息率 (DY TTM) | 3.18% |
| 5年平均股息收益率 | 3.22% |
| 股息支付比率 | 268.80% |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 15 Apr 2025 | 13 Feb 2025 | 15 May 2025 | 1.64 现金 |
| 15 Jan 2025 | 30 Oct 2024 | 14 Feb 2025 | 1.64 现金 |
| 15 Oct 2024 | 06 Sep 2024 | 15 Nov 2024 | 1.55 现金 |
| 15 Jul 2024 | 20 Jun 2024 | 15 Aug 2024 | 1.55 现金 |
| 12 Apr 2024 | 15 Feb 2024 | 15 May 2024 | 1.55 现金 |
| 12 Jan 2024 | 27 Oct 2023 | 15 Feb 2024 | 1.55 现金 |
| 12 Oct 2023 | 08 Sep 2023 | 15 Nov 2023 | 1.48 现金 |
| 13 Jul 2023 | 22 Jun 2023 | 15 Aug 2023 | 1.48 现金 |
| 13 Apr 2023 | 16 Feb 2023 | 15 May 2023 | 1.48 现金 |
| 12 Jan 2023 | 28 Oct 2022 | 15 Feb 2023 | 1.48 现金 |
| 13 Oct 2022 | 09 Sep 2022 | 15 Nov 2022 | 1.41 现金 |
| 14 Jul 2022 | 23 Jun 2022 | 15 Aug 2022 | 1.41 现金 |
| 13 Apr 2022 | 17 Feb 2022 | 16 May 2022 | 1.41 现金 |
| 13 Jan 2022 | 29 Oct 2021 | 15 Feb 2022 | 1.41 现金 |
| 14 Oct 2021 | 10 Sep 2021 | 15 Nov 2021 | 1.3 现金 |
| 14 Jul 2021 | 17 Jun 2021 | 16 Aug 2021 | 1.3 现金 |
| 14 Apr 2021 | 18 Feb 2021 | 14 May 2021 | 1.3 现金 |
| 14 Jan 2021 | 30 Oct 2020 | 16 Feb 2021 | 1.3 现金 |
| 14 Oct 2020 | 11 Sep 2020 | 16 Nov 2020 | 1.18 现金 |
| 14 Jul 2020 | 17 Jun 2020 | 14 Aug 2020 | 1.18 现金 |
| 14 Apr 2020 | 20 Feb 2020 | 15 May 2020 | 1.18 现金 |
| 14 Jan 2020 | 01 Nov 2019 | 14 Feb 2020 | 1.18 现金 |
| 11 Oct 2019 | 06 Sep 2019 | 15 Nov 2019 | 1.07 现金 |
| 12 Jul 2019 | 21 Jun 2019 | 15 Aug 2019 | 1.07 现金 |
| 12 Apr 2019 | 22 Feb 2019 | 15 May 2019 | 1.07 现金 |
| 14 Jan 2019 | 02 Nov 2018 | 15 Feb 2019 | 1.07 现金 |
| 12 Oct 2018 | 08 Sep 2018 | 15 Nov 2018 | 0.96 现金 |
| 12 Jul 2018 | 15 Jun 2018 | 15 Aug 2018 | 0.96 现金 |
| 12 Apr 2018 | 15 Feb 2018 | 15 May 2018 | 0.96 现金 |
| 11 Jan 2018 | 27 Oct 2017 | 15 Feb 2018 | 0.71 现金 |
| 12 Oct 2017 | 08 Sep 2017 | 15 Nov 2017 | 0.64 现金 |
| 12 Jul 2017 | 22 Jun 2017 | 15 Aug 2017 | 0.64 现金 |
| 11 Apr 2017 | 16 Feb 2017 | 15 May 2017 | 0.64 现金 |
| 11 Jan 2017 | 28 Oct 2016 | 15 Feb 2017 | 0.64 现金 |
| 12 Oct 2016 | 09 Sep 2016 | 15 Nov 2016 | 0.57 现金 |
| 13 Jul 2016 | 16 Jun 2016 | 15 Aug 2016 | 0.57 现金 |
| 13 Apr 2016 | 18 Feb 2016 | 16 May 2016 | 0.57 现金 |
| 13 Jan 2016 | 30 Oct 2015 | 16 Feb 2016 | 0.57 现金 |
| 13 Oct 2015 | 11 Sep 2015 | 16 Nov 2015 | 0.51 现金 |
| 13 Jul 2015 | 18 Jun 2015 | 14 Aug 2015 | 0.51 现金 |
| 13 Apr 2015 | 19 Feb 2015 | 15 May 2015 | 0.51 现金 |
| 13 Jan 2015 | 20 Oct 2014 | 13 Feb 2015 | 0.49 现金 |
| 10 Oct 2014 | 19 Sep 2014 | 17 Nov 2014 | 0.42 现金 |
| 11 Jul 2014 | 19 Jun 2014 | 15 Aug 2014 | 0.42 现金 |
| 11 Apr 2014 | 20 Feb 2014 | 15 May 2014 | 0.42 现金 |
| 13 Jan 2014 | 12 Dec 2013 | 14 Feb 2014 | 0.4 现金 |
| 10 Oct 2013 | 19 Sep 2013 | 15 Nov 2013 | 0.4 现金 |
| 11 Jul 2013 | 20 Jun 2013 | 15 Aug 2013 | 0.4 现金 |
| 11 Apr 2013 | 15 Feb 2013 | 15 May 2013 | 0.4 现金 |
| 11 Jan 2013 | 04 Jan 2013 | 15 Feb 2013 | 0.4 现金 |
| 显示更多 | |||
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2025 | 3.28 | 2 | 1.44 |
| 2024 | 6.20 | 4 | 3.49 |
| 2023 | 5.92 | 4 | 3.82 |
| 2022 | 5.64 | 4 | 3.49 |
| 2021 | 5.20 | 4 | 3.84 |
| 2020 | 4.72 | 4 | 4.41 |
| 2019 | 4.28 | 4 | 4.83 |
| 2018 | 3.59 | 4 | 3.89 |
| 2017 | 2.56 | 4 | 2.65 |
| 2016 | 2.28 | 4 | 3.64 |
| 2015 | 2.02 | 4 | 3.41 |
| 2014 | 1.66 | 4 | 2.54 |
| 2013 | 1.60 | 4 | 3.03 |
| 显示更多 | |||
投资组合